Literature DB >> 20192119

Inhibition of BCL2 expression and activity increases H460 sensitivity to the growth inhibitory effects of polyphenon E.

Theodor Borgovan1, John-Paul S Bellistri, Kristen N Slack, Levy Kopelovich, Manisha Desai, Andrew K Joe.   

Abstract

The anti-cancer properties of the green tea-derived mixture Polyphenon E (Poly E) have been demonstrated in a variety of cell culture and animal models. We recently discovered that the H460 lung cancer cell line is markedly resistant to the growth inhibitory effects of Poly E compared with SW480 colon and Flo-1 esophageal cancer cells. We investigated the mechanism of H460 resistance by comparing gene expression profiles of Poly E-sensitive and -resistant cells. Unsupervised hierarchical clustering revealed that Poly E-sensitive cells clustered separately from Poly E-resistant cells, and 6,242 genes were differentially expressed between the two groups at the 0.01 level of significance. We discovered that BCL2 gene and protein expression were significantly higher in H460 cells compared with SW480 and Flo-1 cells (10.60-fold higher gene expression; P < 0.0001). Inhibition of BCL2 expression and activity, using siRNA and the small molecule inhibitor HA14-1 respectively, restored sensitivity to Poly E and induced BCL2-related apoptosis by decreasing mitochondrial membrane potential and inducing PARP cleavage. Our results suggest that increased BCL2 expression may contribute to H460 resistance to the growth inhibitory effects of Poly E. If validated in additional laboratory and clinical models, BCL2 could ultimately be used as a marker of Poly E resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20192119      PMCID: PMC6361110     

Source DB:  PubMed          Journal:  J Exp Ther Oncol        ISSN: 1359-4117


  3 in total

1.  Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.

Authors:  Andrew K Joe; Felice Schnoll-Sussman; Robert S Bresalier; Julian A Abrams; Hanina Hibshoosh; Ken Cheung; Richard A Friedman; Chung S Yang; Ginger L Milne; Diane D Liu; J Jack Lee; Kazeem Abdul; Michelle Bigg; Jessica Foreman; Tao Su; Xiaomei Wang; Aqeel Ahmed; Alfred I Neugut; Esther Akpa; Scott M Lippman; Marjorie Perloff; Powel H Brown; Charles J Lightdale
Journal:  Cancer Prev Res (Phila)       Date:  2015-10-15

2.  Letters to the editor.

Authors: 
Journal:  Ochsner J       Date:  2013

3.  Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems.

Authors:  Bárbara Pinto; Pedro Novais; Ana C Henriques; Juliana Carvalho-Tavares; Patrícia M A Silva; Hassan Bousbaa
Journal:  Pharmaceutics       Date:  2022-06-06       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.